.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
EMPA-REG OUTCOME examined empagliflozin in patients with type 2 diabetes and established cardiovascular disease. Compared with placebo, empagliflozin reduced cardiovascular death, hospitalization for heart failure and all-cause mortality. The magnitude and early separation of the curves helped establish SGLT2 inhibitors as cardiovascular risk-modifying therapies. For general physicians, the study is relevant when choosing glucose-lowering therapy for patients with high cardiovascular risk because the clinical goal extends beyond HbA1c. Empagliflozin's effects on heart-failure hospitalization and cardiovascular mortality also connect diabetes care directly with cardiology and nephrology. Safe prescribing requires attention to kidney function, volume status, genital infections and temporary discontinuation during acute illness. The major practice lesson is to phenotype the patient first: a person with established ASCVD, heart failure or CKD may benefit from a therapy selected partly for organ protection rather than glucose reduction alone. The trial helped establish the modern cardiometabolic approach to type 2 diabetes treatment.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
EMPA-REG OUTCOME examined empagliflozin in patients with type 2 diabetes and established cardiovascular disease. Compared with placebo, empagliflozin reduced cardiovascular death, hospitalization for heart failure and all-cause mortality. The magnitude and early separation of the curves helped establish SGLT2 inhibitors as cardiovascular risk-modifying therapies. For general physicians, the study is relevant when choosing glucose-lowering therapy for patients with high cardiovascular risk because the clinical goal extends beyond HbA1c. Empagliflozin's effects on heart-failure hospitalization and cardiovascular mortality also connect diabetes care directly with cardiology and nephrology. Safe prescribing requires attention to kidney function, volume status, genital infections and temporary discontinuation during acute illness. The major practice lesson is to phenotype the patient first: a person with established ASCVD, heart failure or CKD may benefit from a therapy selected partly for organ protection rather than glucose reduction alone. The trial helped establish the modern cardiometabolic approach to type 2 diabetes treatment.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
